Tadahiko Kikugawa, Nozomu Tanji, Noriyoshi Miura, Takashi Ochi, Atsushi Nishikawa, Yuki Miyauchi, Takeshi Sato, Hitoshi Hamada, Atsushi Matsumoto and Masayoshi Yokoyama
Objective: To evaluate biochemical recurrence-free survival (b-RFS) in patients with Gleason score 7 prostate cancers treated with external beam radiotherapy at Ehime University Hospital. Materials and Methods: Between January 2003 and October 2009, 63 patients with Gleason score 7 prostate cancers were treated with three-dimensional conformal radiotherapy (3D-CRT) at our institute. Of the 63 patients analyzed, 41 and 22 had a primary Gleason pattern of 3 and 4 carcinoma, respectively. Neoadjuvant hormonal therapy had been given to 37 patients (59%) for 6 months prior to radiotherapy. The American Society for Therapeutic Radiology and Oncology Phoenix consensus definition was used to determine the b-RFS after treatment. Results: The overall b-RFS rate at 5 year was 71% and 77% for Gleason score 3+4 and 4+3 prostate cancer, respectively. The overall b-RFS at 5 year was 59% and 86% in Gleason score 3+4 patients with and without neoadjuvant hormonal therapy for 6 months, respectively. Conclusions: Our results indicate that the 5 year b-RFS outcome with 3D-CRT is not dependent on Gleason score 3+4 versus 4+3 histological features, or on neoadjuvant hormonal therapy for 6 months in patients with a Gleason score of 3+4.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 